Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukemic stem cells: identification and clinical application.

Diana Hanekamp1, Jacqueline Cloos2,3, Gerrit Jan Schuurhuis1

  • 1Department of Hematology, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.

International Journal of Hematology
|March 31, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

HemaSphere·2026
Same author

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

American journal of hematology·2026
Same author

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.

Blood advances·2026
Same author

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea.

Blood advances·2026
Same author

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Blood·2025
Same author

Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

Leukemia·2025
Same journal

Long-term treatment-free remission in CML after early dasatinib discontinuation due to interstitial pneumonitis.

International journal of hematology·2026
Same journal

Correction to: Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.

International journal of hematology·2026
Same journal

The efficacy of prophylactic tranexamic acid in patients with hematologic malignancy: a systematic review and meta-analysis.

International journal of hematology·2026
Same journal

Current status and challenges of TCR-T cell therapy for AML/MDS.

International journal of hematology·2026
Same journal

Efficacy and safety of maribavir in Japanese patients with post-transplant cytomegalovirus infections: a phase III study.

International journal of hematology·2026
Same journal

Prognostic impact of WT1 dynamics in peripheral blood before and after allogeneic HSCT in patients with AML and MDS.

International journal of hematology·2026
See all related articles

Leukemic stem cells (LSCs) drive acute myeloid leukemia (AML) relapse due to self-renewal and drug resistance. Understanding LSC heterogeneity is key to improving AML treatment outcomes and preventing disease recurrence.

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Leukemic stem cells (LSCs) are a critical subpopulation in acute myeloid leukemia (AML), responsible for disease initiation and relapse.
  • LSCs exhibit unique stem cell properties like self-renewal and drug resistance, differentiating them from bulk leukemia cells.
  • Evidence suggests LSCs can engraft and initiate human AML in immune-compromised mouse models, confirming their role.

Purpose of the Study:

  • To enhance the understanding of leukemic stem cell (LSC) heterogeneity in acute myeloid leukemia (AML).
  • To explore advanced techniques for identifying and characterizing diverse LSC phenotypes.
  • To provide insights for improved risk stratification, clinical decision-making, and novel therapeutic target identification in AML.

Main Methods:

Keywords:
Acute myeloid leukemiaFlow cytometryImmunophenotypicLeukemic stem cells

Related Experiment Videos

  • Utilizing multicolor flow cytometry for detailed cell surface marker analysis.
  • Employing side-population assays to identify cells with stem cell-like properties.
  • Applying the aldehyde dehydrogenase (ALDH) assay to further characterize LSC populations.

Main Results:

  • The study highlights the complex heterogeneity of LSC phenotypes beyond the commonly studied CD34+/CD38- compartment.
  • Advanced assays reveal distinct LSC subpopulations with varying stem cell characteristics.
  • These findings underscore the importance of a nuanced view of LSC biology.

Conclusions:

  • A deeper understanding of LSC heterogeneity is essential for advancing AML treatment strategies.
  • Identifying and targeting specific LSC phenotypes can lead to more effective therapies and potentially prevent relapse.
  • These efforts aim to improve patient outcomes in AML by addressing the root cause of disease persistence.